We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Read MoreHide Full Article
J&J (JNJ - Free Report) announced positive data from the phase III ICONIC-TOTAL study evaluating its investigational oral peptide, icotrokinra, for the treatment of plaque psoriasis (PsO) in patients with at least moderate severity affecting sensitive areas.
The study met its primary endpoint – 57% of patients treated with the once-daily drug for 16 weeks achieved significant skin clearance compared to 6% of those who received placebo. This was measured using the Investigator’s Global Assessment (IGA), a clinical measure to assess the overall severity of a condition or disease.
More on J&J’s ICONIC-TOTAL Study Results
The study focused on patients aged 12 years and older suffering from psoriasis in difficult-to-treat areas such as the scalp, genitals, and hands/feet, which are often challenging to manage and can significantly impair a patient's quality of life.
Per J&J, 66% of patients with scalp psoriasis who received icotrokinra achieved site-specific clear or almost clear skin compared to 11% in the placebo group. In the genital psoriasis subgroup, 77% of patients treated with the drug achieved significant skin clearance versus 21% receiving placebo.
In the smaller hand/foot subgroup, 42% of treated patients achieved skin clearance compared to 26% receiving placebo.
JNJ’s Stock Performance
Year to date, shares of J&J have gained nearly 7% against the industry’s 6% decline.
Image Source: Zacks Investment Research
Recent Developments With J&J’s Icotrokinra
Icotrokinra is being jointly developed by J&J and Protagonist Therapeutics (PTGX - Free Report) under a license and collaboration agreement signed in 2017. Per the terms, J&J holds exclusive worldwide rights to develop the drug in phase II studies and beyond.
The ICONIC-TOTAL study is part of J&J’s late-stage ICONIC clinical program evaluating icotrokinra across PsO and psoriatic arthritis indications. Last year, the company reported top-line results from the late-stage ICONIC-LEAD study, which evaluated the drug in patients with moderate-to-severe plaque PsO. That study also achieved its primary endpoint.
More recently, J&J and Protagonist also reported new data from two phase III studies — ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 — which evaluated icotrokinra against both placebo and Bristol Myers’ (BMY - Free Report) psoriasis drug, Sotyktu. Both studies met their primary endpoints and demonstrated the drug’s superiority over Bristol Myers’ Sotyktu.
Based on the above outperformance, J&J started the phase III ICONIC-ASCEND study — a head-to-head study comparing icotrokinra with J&J’s own blockbuster immunology drug Stelara — in patients with moderate-to-severe plaque PsO. Through icotrokinra, J&J intends to provide a more convenient treatment option for patients than Stelara, which is administered through an injection and is currently facing generic erosion in the United States.
Apart from dermatology, J&J and Protagonist are also exploring the drug’s potential in the inflammatory bowel disease (IBD) space. Earlier this year, the companies reported positive results from the phase IIb ANTHEM-UC study, which evaluated the drug in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical response across all dose groups. J&J believes that the drug has the potential to deliver peak non-risk-adjusted operational sales of $5 billion
Image: Bigstock
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
J&J (JNJ - Free Report) announced positive data from the phase III ICONIC-TOTAL study evaluating its investigational oral peptide, icotrokinra, for the treatment of plaque psoriasis (PsO) in patients with at least moderate severity affecting sensitive areas.
The study met its primary endpoint – 57% of patients treated with the once-daily drug for 16 weeks achieved significant skin clearance compared to 6% of those who received placebo. This was measured using the Investigator’s Global Assessment (IGA), a clinical measure to assess the overall severity of a condition or disease.
More on J&J’s ICONIC-TOTAL Study Results
The study focused on patients aged 12 years and older suffering from psoriasis in difficult-to-treat areas such as the scalp, genitals, and hands/feet, which are often challenging to manage and can significantly impair a patient's quality of life.
Per J&J, 66% of patients with scalp psoriasis who received icotrokinra achieved site-specific clear or almost clear skin compared to 11% in the placebo group. In the genital psoriasis subgroup, 77% of patients treated with the drug achieved significant skin clearance versus 21% receiving placebo.
In the smaller hand/foot subgroup, 42% of treated patients achieved skin clearance compared to 26% receiving placebo.
JNJ’s Stock Performance
Year to date, shares of J&J have gained nearly 7% against the industry’s 6% decline.
Image Source: Zacks Investment Research
Recent Developments With J&J’s Icotrokinra
Icotrokinra is being jointly developed by J&J and Protagonist Therapeutics (PTGX - Free Report) under a license and collaboration agreement signed in 2017. Per the terms, J&J holds exclusive worldwide rights to develop the drug in phase II studies and beyond.
The ICONIC-TOTAL study is part of J&J’s late-stage ICONIC clinical program evaluating icotrokinra across PsO and psoriatic arthritis indications. Last year, the company reported top-line results from the late-stage ICONIC-LEAD study, which evaluated the drug in patients with moderate-to-severe plaque PsO. That study also achieved its primary endpoint.
More recently, J&J and Protagonist also reported new data from two phase III studies — ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 — which evaluated icotrokinra against both placebo and Bristol Myers’ (BMY - Free Report) psoriasis drug, Sotyktu. Both studies met their primary endpoints and demonstrated the drug’s superiority over Bristol Myers’ Sotyktu.
Based on the above outperformance, J&J started the phase III ICONIC-ASCEND study — a head-to-head study comparing icotrokinra with J&J’s own blockbuster immunology drug Stelara — in patients with moderate-to-severe plaque PsO. Through icotrokinra, J&J intends to provide a more convenient treatment option for patients than Stelara, which is administered through an injection and is currently facing generic erosion in the United States.
Apart from dermatology, J&J and Protagonist are also exploring the drug’s potential in the inflammatory bowel disease (IBD) space. Earlier this year, the companies reported positive results from the phase IIb ANTHEM-UC study, which evaluated the drug in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical response across all dose groups. J&J believes that the drug has the potential to deliver peak non-risk-adjusted operational sales of $5 billion
Johnson & Johnson Price
Johnson & Johnson price | Johnson & Johnson Quote
JNJ’s Zacks Ranks
J&J currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.